Tectonic Advisors LLC Acquires 54,068 Shares of Pfizer Inc. $PFE

Key Points

• Tectonic Advisors LLC increased its holdings in Pfizer Inc. by 22.1%, acquiring an additional 54,068 shares to reach a total of 298,687 shares worth $7.24 million.
• Several institutional investors, including Vanguard Group Inc. and Amundi, have also increased their investments in Pfizer, contributing to 68.36% of its stock being held by hedge funds and institutional investors.
• Analyst ratings for Pfizer show a consensus of "Hold", with an average price target of $28.41, despite mixed ratings from multiple firms.

Tectonic Advisors LLC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 22.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 298,687 shares of the biopharmaceutical company's stock after acquiring an additional 54,068 shares during the period. Tectonic Advisors LLC's holdings in Pfizer were worth $7,240,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Northern Trust Corp raised its position in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares during the period. Amundi raised its position in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Invesco Ltd. raised its position in Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after purchasing an additional 838,198 shares during the period. Finally, Deutsche Bank AG raised its position in Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a "neutral" rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $28.41.

Pfizer Stock Performance

Shares of PFE stock opened at $25.67 on Thursday. The firm has a market cap of $145.95 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The company's 50 day moving average is $24.79 and its 200 day moving average is $24.15. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.